{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T14:01:51Z","timestamp":1783778511317,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T00:00:00Z","timestamp":1531180800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41401-018-0055-1","type":"journal-article","created":{"date-parts":[[2018,7,10]],"date-time":"2018-07-10T12:37:16Z","timestamp":1531226236000},"page":"500-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Expression of the oxygen-sensitive transcription factor subunit HIF-1\u03b1 in patients suffering from secondary Raynaud syndrome"],"prefix":"10.1038","volume":"40","author":[{"given":"Lukas Andreas","family":"Heger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Kerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Hortmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Mauler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Stallmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Duerschmied","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Bode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Hehrlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,7,10]]},"reference":[{"key":"55_CR1","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/S0959-437X(98)80016-6","volume":"8","author":"GL Semenza","year":"1998","unstructured":"Semenza GL. Hypoxia-inducible factor 1: master regulator of O2 homeostasis. Curr Opin Genet Dev. 1998;8:588\u201394.","journal-title":"Curr Opin Genet Dev"},{"key":"55_CR2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/ki.1997.77","volume":"51","author":"GL Semenza","year":"1997","unstructured":"Semenza GL, Agani F, Booth G, Forsythe J, Iyer N, Jiang BH, et al. Structural and functional analysis of hypoxia-inducible factor 1. Kidney Int. 1997;51:553\u20135.","journal-title":"Kidney Int"},{"key":"55_CR3","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","volume":"92","author":"GL Wang","year":"1995","unstructured":"Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92:5510\u20134.","journal-title":"Proc Natl Acad Sci USA"},{"key":"55_CR4","doi-asserted-by":"publisher","first-page":"5375","DOI":"10.1074\/jbc.272.9.5375","volume":"272","author":"PJ Lee","year":"1997","unstructured":"Lee PJ, Jiang BH, Chin BY, Iyer NV, Alam J, Semenza GL, et al. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem. 1997;272:5375\u201381.","journal-title":"J Biol Chem"},{"key":"55_CR5","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1006\/bbrc.1998.8543","volume":"245","author":"J Hu","year":"1998","unstructured":"Hu J, Discher DJ, Bishopric NH, Webster KA. Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-inducible factor-1 binding site on the antisense strand. Biochem Biophys Res Commun. 1998;245:894\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"55_CR6","first-page":"1310","volume":"125","author":"RZ Miao","year":"2012","unstructured":"Miao RZ, Liu LQ, Chen L, Li Z, Li LP, Guo RL, et al. Activity of heme oxygenase-1 affects expression levels of hypoxia inducible factor-1 gene in vitro. Chin Med J. 2012;125:1310\u20135.","journal-title":"Chin Med J"},{"key":"55_CR7","first-page":"1474","volume":"2000","author":"GL Semenza","year":"1985","unstructured":"Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 1985;2000:1474\u201380.","journal-title":"J Appl Physiol"},{"key":"55_CR8","first-page":"107","volume":"1755","author":"JI Bardos","year":"2005","unstructured":"Bardos JI, Ashcroft M. Negative and positive regulation of HIF-1: a complex network. Biochim Biophys Acta. 2005;1755:107\u201320.","journal-title":"Biochim Biophys Acta"},{"key":"55_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.cellimm.2016.04.001","volume":"303","author":"W Deng","year":"2016","unstructured":"Deng W, Feng X, Li X, Wang D, Sun L. Hypoxia-inducible factor 1 in autoimmune diseases. Cell Immunol. 2016;303:7\u201315.","journal-title":"Cell Immunol"},{"key":"55_CR10","doi-asserted-by":"crossref","first-page":"824972","DOI":"10.1155\/2011\/824972","volume":"2011","author":"TW Hal van","year":"2011","unstructured":"van Hal TW, van Bon L, Radstake TR. A system out of breath: how hypoxia possibly contributes to the pathogenesis of systemic sclerosis. Int J Rheumatol. 2011;2011:824972.","journal-title":"Int J Rheumatol"},{"key":"55_CR11","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.rdc.2005.04.006","volume":"31","author":"T Grader-Beck","year":"2005","unstructured":"Grader-Beck T, Wigley FM. Raynaud\u2019s phenomenon in mixed connective tissue disease. Rheum Dis Clin North Am. 2005;31:465\u201381.","journal-title":"Rheum Dis Clin North Am"},{"issue":"Suppl 4","key":"55_CR12","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/ard.50.Suppl_4.839","volume":"50","author":"JJ Belch","year":"1991","unstructured":"Belch JJ. Raynaud\u2019s phenomenon: its relevance to scleroderma. Ann Rheum Dis. 1991;50(Suppl 4):839\u201345.","journal-title":"Ann Rheum Dis"},{"key":"55_CR13","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S1062-0303(96)80013-6","volume":"14","author":"MW Kaufman","year":"1996","unstructured":"Kaufman MW, All AC. Raynaud\u2019s disease: patient education as a primary nursing intervention. J Vasc Nurs. 1996;14:34\u20139.","journal-title":"J Vasc Nurs"},{"key":"55_CR14","first-page":"pii: 1125","volume":"2014","author":"A Herrick","year":"2014","unstructured":"Herrick A, Muir L. Raynaud\u2019s phenomenon (secondary). BMJ Clin Evid. 2014;2014:pii: 1125.","journal-title":"BMJ Clin Evid"},{"issue":"Suppl 3","key":"55_CR15","first-page":"iii33","volume":"45","author":"C Sunderkotter","year":"2006","unstructured":"Sunderkotter C, Riemekasten G. Pathophysiology and clinical consequences of Raynaud\u2019s phenomenon related to systemic sclerosis. Rheumatology. 2006;45(Suppl 3):iii33\u20135.","journal-title":"Rheumatology"},{"key":"55_CR16","first-page":"485","volume":"10","author":"EC LeRoy","year":"1992","unstructured":"LeRoy EC, Medsger TA Jr. Raynaud\u2019s phenomenon: a proposal for classification. Clin Exp Rheumatol. 1992;10:485\u20138.","journal-title":"Clin Exp Rheumatol"},{"key":"55_CR17","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1002\/art.23074","volume":"56","author":"JH Distler","year":"2007","unstructured":"Distler JH, Jungel A, Pileckyte M, Zwerina J, Michel BA, Gay RE, et al. Hypoxia-induced increase in the production of extracellular matrix proteins in systemic sclerosis. Arthritis Rheum. 2007;56:4203\u201315.","journal-title":"Arthritis Rheum"},{"key":"55_CR18","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.autrev.2010.09.015","volume":"10","author":"J Wei","year":"2011","unstructured":"Wei J, Bhattacharyya S, Tourtellotte WG, Varga J. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev. 2011;10:267\u201375.","journal-title":"Autoimmun Rev"},{"key":"55_CR19","doi-asserted-by":"publisher","first-page":"3985","DOI":"10.1002\/art.20676","volume":"50","author":"JH Korn","year":"2004","unstructured":"Korn JH, Mayes M, Matucci Cerinic M, Rainisio M, Pope J, Hachulla E, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985\u201393.","journal-title":"Arthritis Rheum"},{"key":"55_CR20","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.44.11.754","volume":"44","author":"JS Mohrland","year":"1985","unstructured":"Mohrland JS, Porter JM, Smith EA, Belch J, Simms MH. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud\u2019s syndrome. Ann Rheum Dis. 1985;44:754\u201360.","journal-title":"Ann Rheum Dis"},{"key":"55_CR21","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1024\/0301-1526.33.3.137","volume":"33","author":"A Creutzig","year":"2004","unstructured":"Creutzig A, Lehmacher W, Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. Vasa. 2004;33:137\u201344.","journal-title":"Vasa"},{"key":"55_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic M, Denton CP, Furst DE, Mayes MD, Hsu VM, Carpentier P, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2011;70:32\u20138.","journal-title":"Ann Rheum Dis"},{"key":"55_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2013.09.019","volume":"63","author":"AS Jaipersad","year":"2014","unstructured":"Jaipersad AS, Lip GY, Silverman S, Shantsila E. The role of monocytes in angiogenesis and atherosclerosis. J Am Coll Cardiol. 2014;63:1\u201311.","journal-title":"J Am Coll Cardiol"},{"key":"55_CR24","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.imbio.2008.07.016","volume":"213","author":"L Elbarghati","year":"2008","unstructured":"Elbarghati L, Murdoch C, Lewis CE. Effects of hypoxia on transcription factor expression in human monocytes and macrophages. Immunobiology. 2008;213:899\u2013908.","journal-title":"Immunobiology"},{"key":"55_CR25","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1046\/j.1523-1747.1999.00476.x","volume":"112","author":"P Sambo","year":"1999","unstructured":"Sambo P, Jannino L, Candela M, Salvi A, Donini M, Dusi S, et al. Monocytes of patients with systemic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion. J Invest Dermatol. 1999;112:78\u201384.","journal-title":"J Invest Dermatol"},{"key":"55_CR26","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/ar3167","volume":"12","author":"RB Christmann","year":"2010","unstructured":"Christmann RB, Lafyatis R. The cytokine language of monocytes and macrophages in systemic sclerosis. Arthritis Res Ther. 2010;12:146.","journal-title":"Arthritis Res Ther"},{"key":"55_CR27","first-page":"51","volume":"80","author":"JE Ziello","year":"2007","unstructured":"Ziello JE, Jovin IS, Huang Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med. 2007;80:51\u201360.","journal-title":"Yale J Biol Med"},{"key":"55_CR28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1042\/BJ20051839","volume":"396","author":"S Frede","year":"2006","unstructured":"Frede S, Stockmann C, Freitag P, Fandrey J. Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44\/42 MAPK and NF-kappaB. Biochem J. 2006;396:517\u201327.","journal-title":"Biochem J"},{"key":"55_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1475-2840-13-52","volume":"13","author":"G Li","year":"2014","unstructured":"Li G, Lu WH, Ai R, Yang JH, Chen F, Tang ZZ. The relationship between serum hypoxia-inducible factor 1alpha and coronary artery calcification in asymptomatic type 2 diabetic patients. Cardiovasc Diabetol. 2014;13:52.","journal-title":"Cardiovasc Diabetol"},{"key":"55_CR30","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1089\/ars.2013.5673","volume":"20","author":"TD Hull","year":"2014","unstructured":"Hull TD, Agarwal A, George JF. The mononuclear phagocyte system in homeostasis and disease: a role for heme oxygenase-1. Antioxid Redox Signal. 2014;20:1770\u201388.","journal-title":"Antioxid Redox Signal"},{"key":"55_CR31","doi-asserted-by":"publisher","first-page":"3437","DOI":"10.1093\/eurheartj\/ehv544","volume":"36","author":"P Wenzel","year":"2015","unstructured":"Wenzel P, Rossmann H, Muller C, Kossmann S, Oelze M, Schulz A, et al. Heme oxygenase-1 suppresses a pro-inflammatory phenotype in monocytes and determines endothelial function and arterial hypertension in mice and humans. Eur Heart J. 2015;36:3437\u201346.","journal-title":"Eur Heart J"},{"key":"55_CR32","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1136\/ard.2007.073684","volume":"66","author":"ME Hettema","year":"2007","unstructured":"Hettema ME, Zhang D, Bootsma H, Kallenberg CG. Bosentan therapy for patients with severe Raynaud\u2019s phenomenon in systemic sclerosis. Ann Rheum Dis. 2007;66:1398\u20139.","journal-title":"Ann Rheum Dis"},{"key":"55_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/03009740310004711","volume":"33","author":"B Marasini","year":"2004","unstructured":"Marasini B, Massarotti M, Bottasso B, Coppola R, Del Papa N, Maglione W, et al. Comparison between iloprost and alprostadil in the treatment of Raynaud\u2019s phenomenon. Scand J Rheumatol. 2004;33:253\u20136.","journal-title":"Scand J Rheumatol"},{"key":"55_CR34","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1080\/03009740802629432","volume":"38","author":"J Wipff","year":"2009","unstructured":"Wipff J, Dieude P, Avouac J, Tiev K, Hachulla E, Granel B, et al. Association of hypoxia-inducible factor 1A (HIF1A) gene polymorphisms with systemic sclerosis in a French European Caucasian population. Scand J Rheumatol. 2009;38:291\u20134.","journal-title":"Scand J Rheumatol"},{"key":"55_CR35","first-page":"3810","volume":"117","author":"DF Higgins","year":"2007","unstructured":"Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest. 2007;117:3810\u201320.","journal-title":"J Clin Invest"},{"key":"55_CR36","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/ki.1997.79","volume":"51","author":"RH Wenger","year":"1997","unstructured":"Wenger RH, Kvietikova I, Rolfs A, Gassmann M, Marti HH. Hypoxia-inducible factor-1 alpha is regulated at the post-mRNA level. Kidney Int. 1997;51:560\u20133.","journal-title":"Kidney Int"},{"key":"55_CR37","doi-asserted-by":"publisher","first-page":"389582","DOI":"10.1155\/2014\/389582","volume":"2014","author":"B Grygiel-Gorniak","year":"2014","unstructured":"Grygiel-Gorniak B, Puszczewicz M. Oxidative damage and antioxidative therapy in systemic sclerosis. Mediat Inflamm. 2014;2014:389582.","journal-title":"Mediat Inflamm"},{"key":"55_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.freeradbiomed.2008.10.047","volume":"46","author":"V Pialoux","year":"2009","unstructured":"Pialoux V, Mounier R, Brown AD, Steinback CD, Rawling JM, Poulin MJ. Relationship between oxidative stress and HIF-1 alpha mRNA during sustained hypoxia in humans. Free Radic Biol Med. 2009;46:321\u20136.","journal-title":"Free Radic Biol Med"},{"key":"55_CR39","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/jmcb\/mjs002","volume":"4","author":"Y Zhang","year":"2012","unstructured":"Zhang Y, Li L, Hua Y, Nunn JM, Dong F, Yanagisawa M, et al. Cardiac-specific knockout of ET(A) receptor mitigates low ambient temperature-induced cardiac hypertrophy and contractile dysfunction. J Mol Cell Biol. 2012;4:97\u2013107.","journal-title":"J Mol Cell Biol"},{"key":"55_CR40","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3109\/10715762.2012.669041","volume":"46","author":"H Niecknig","year":"2012","unstructured":"Niecknig H, Tug S, Reyes BD, Kirsch M, Fandrey J, Berchner-Pfannschmidt U. Role of reactive oxygen species in the regulation of HIF-1 by prolyl hydroxylase 2 under mild hypoxia. Free Radic Res. 2012;46:705\u201317.","journal-title":"Free Radic Res"},{"key":"55_CR41","doi-asserted-by":"publisher","first-page":"5106","DOI":"10.1128\/MCB.00060-08","volume":"28","author":"AA Qutub","year":"2008","unstructured":"Qutub AA, Popel AS. Reactive oxygen species regulate hypoxia-inducible factor 1alpha differentially in cancer and ischemia. Mol Cell Biol. 2008;28:5106\u201319.","journal-title":"Mol Cell Biol"},{"key":"55_CR42","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s10067-015-3119-3","volume":"35","author":"S Bellando-Randone","year":"2016","unstructured":"Bellando-Randone S, Lepri G, Bruni C, Blagojevic J, Radicati A, Cometi L, et al. Combination therapy with Bosentan and Sildenafil improves Raynaud\u2019s phenomenon and fosters the recovery of microvascular involvement in systemic sclerosis. Clin Rheumatol. 2016;35:127\u201332.","journal-title":"Clin Rheumatol"},{"key":"55_CR43","first-page":"493","volume":"30","author":"F Hafner","year":"2011","unstructured":"Hafner F, Thomas G, Froehlich H, Steidl K, Brodmann M. Effect of a sequential therapy of bosentan and iloprost versus a monotherapy with bosentan in the treatment of scleroderma related digital ulcers. Int Angiol. 2011;30:493\u20135.","journal-title":"Int Angiol"},{"key":"55_CR44","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1111\/j.1365-2125.1995.tb05784.x","volume":"40","author":"W Cawello","year":"1995","unstructured":"Cawello W, Leonhardt A, Schweer H, Seyberth HW, Bonn R, Lomeli AL. Dose proportional pharmacokinetics of alprostadil (prostaglandin E1) in healthy volunteers following intravenous infusion. Br J Clin Pharmacol. 1995;40:273\u20136.","journal-title":"Br J Clin Pharmacol"},{"key":"55_CR45","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jns.2017.01.039","volume":"375","author":"L Xue","year":"2017","unstructured":"Xue L, Chen H, Lu K, Huang J, Duan H, Zhao Y. Clinical significance of changes in serum neuroglobin and HIF-1alpha concentrations during the early-phase of acute ischemic stroke. J Neurol Sci. 2017;375:52\u20137.","journal-title":"J Neurol Sci"},{"key":"55_CR46","doi-asserted-by":"publisher","first-page":"16023","DOI":"10.1074\/jbc.275.21.16023","volume":"275","author":"T Ishii","year":"2000","unstructured":"Ishii T, Itoh K, Takahashi S, Sato H, Yanagawa T, Katoh Y, et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J Biol Chem. 2000;275:16023\u20139.","journal-title":"J Biol Chem"},{"key":"55_CR47","doi-asserted-by":"publisher","first-page":"C92","DOI":"10.1152\/ajpcell.2000.278.1.C92","volume":"278","author":"MV Panchenko","year":"2000","unstructured":"Panchenko MV, Farber HW, Korn JH. Induction of heme oxygenase-1 by hypoxia and free radicals in human dermal fibroblasts. Am J Physiol Cell Physiol. 2000;278:C92\u2013101.","journal-title":"Am J Physiol Cell Physiol"},{"key":"55_CR48","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.jacc.2005.09.038","volume":"47","author":"AS Pachori","year":"2006","unstructured":"Pachori AS, Melo LG, Zhang L, Solomon SD, Dzau VJ. Chronic recurrent myocardial ischemic injury is significantly attenuated by pre-emptive adeno-associated virus heme oxygenase-1 gene delivery. J Am Coll Cardiol. 2006;47:635\u201343.","journal-title":"J Am Coll Cardiol"},{"key":"55_CR49","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10059-010-0067-2","volume":"29","author":"A Loboda","year":"2010","unstructured":"Loboda A, Jozkowicz A, Dulak J. HIF-1 and HIF-2 transcription factors--similar but not identical. Mol Cells. 2010;29:435\u201342.","journal-title":"Mol Cells"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41401-018-0055-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-018-0055-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41401-018-0055-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:01:07Z","timestamp":1684616467000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-018-0055-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,10]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["55"],"URL":"https:\/\/doi.org\/10.1038\/s41401-018-0055-1","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,10]]},"assertion":[{"value":"23 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}